Merrimack Pharmaceuticals Stock Price To Earning
| MACKDelisted Stock | USD 11.96 0.12 1.01% |
Merrimack Pharmaceuticals fundamentals help investors to digest information that contributes to Merrimack Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Merrimack Stock. The fundamental analysis module provides a way to measure Merrimack Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Merrimack Pharmaceuticals stock.
Merrimack |
Merrimack Pharmaceuticals Company Price To Earning Analysis
Merrimack Pharmaceuticals' Price to Earnings ratio is typically used for current valuation of a company and is one of the most popular ratios that investors monitor daily. Holding a low PE stock is less risky because when a company's profitability falls, it is likely that earnings will also go down as well. In other words, if you start from a lower position, your downside risk is limited. There are also some investors who believe that low Price to Earnings ratio reflects the low pricing because a given company is in trouble. On the other hand, a higher PE ratio means that investors are paying more for each unit of profit.
Current Merrimack Pharmaceuticals Price To Earning | 65.70 X |
Most of Merrimack Pharmaceuticals' fundamental indicators, such as Price To Earning, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Merrimack Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Generally speaking, the Price to Earnings ratio gives investors an idea of what the market is willing to pay for the company's current earnings.
CompetitionBased on the latest financial disclosure, Merrimack Pharmaceuticals has a Price To Earning of 65 times. This is 154.26% higher than that of the Biotechnology sector and notably higher than that of the Health Care industry. The price to earning for all United States stocks is 128.76% lower than that of the firm.
Merrimack Price To Earning Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Merrimack Pharmaceuticals' direct or indirect competition against its Price To Earning to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Merrimack Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Merrimack Pharmaceuticals by comparing valuation metrics of similar companies.Merrimack Pharmaceuticals is currently under evaluation in price to earning category among its peers.
Merrimack Fundamentals
| Return On Equity | -0.0112 | |||
| Return On Asset | -0.0107 | |||
| Current Valuation | (20.36 M) | |||
| Shares Outstanding | 14.79 M | |||
| Shares Owned By Insiders | 1.19 % | |||
| Shares Owned By Institutions | 62.97 % | |||
| Number Of Shares Shorted | 842.49 K | |||
| Price To Earning | 65.70 X | |||
| Price To Book | 11.38 X | |||
| Gross Profit | (9.1 M) | |||
| EBITDA | (2.18 M) | |||
| Net Income | (1.18 M) | |||
| Cash And Equivalents | 13.36 M | |||
| Cash Per Share | 1.00 X | |||
| Debt To Equity | 33.90 % | |||
| Current Ratio | 31.85 X | |||
| Book Value Per Share | 15.25 X | |||
| Cash Flow From Operations | (1.52 M) | |||
| Short Ratio | 8.65 X | |||
| Earnings Per Share | (0.09) X | |||
| Price To Earnings To Growth | 0.07 X | |||
| Target Price | 4.0 | |||
| Beta | 1.42 | |||
| Market Capitalization | 223.75 M | |||
| Total Asset | 19.19 M | |||
| Retained Earnings | (548.82 M) | |||
| Working Capital | 18.74 M | |||
| Current Asset | 89.62 M | |||
| Current Liabilities | 88.28 M | |||
| Net Asset | 19.19 M |
About Merrimack Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Merrimack Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Merrimack Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Merrimack Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators. You can also try the Price Ceiling Movement module to calculate and plot Price Ceiling Movement for different equity instruments.
Other Consideration for investing in Merrimack Stock
If you are still planning to invest in Merrimack Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Merrimack Pharmaceuticals' history and understand the potential risks before investing.
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. |